


AMENDMENTS TO THE CLAIMS:

Please amend claim 43, as shown below.

This listing of claims will replace all prior versions and listings of claims in the
Application:

Claims 1-35 (cancelled)


Claim 36 (previously presented): A compound having the formula:




Ia

wherein:

R₁ represents a radical selected from the group consisting of



alkoxyalkoxy, polyfluoroalkyl, dialkylaminoalkyl, R₉, ---OR₉,



HAYES SOLOWAY P.C.
3450 E. SUNRISE DRIVE,
SUITE 140
TUCSON, AZ 85718
TEL. 520.882.7623
FAX. 520.882.7643

175 CANAL STREET
MANCHESTER, NH 03101
TEL. 603.668.1400
FAX. 603.668.8567

R_2 and R_3 are each independently selected from the group consisting of straight or branched chain alkyl and hydrogen;

R_4 is a radical selected from the group consisting of a substituted or unsubstituted phenyl radical, an unsubstituted or substituted heterocyclic radical, and $-NR_{12}R_{13}$;

R_5 and R_7 are independently selected from the group consisting of alkoxyalkyl, hydroxyalkyl, polyhydroxyalkyl, aralkyl, R_9 , $-(C=O)R_{14}$ and $-(C=O)R_9$;

R_6 , R_8 , R_{12} , and R_{13} are independently selected from the group consisting of hydrogen, alkyl, alkoxyalkyl, polyfluoroalkyl, hydroxyalkyl, polyhydroxyalkyl, aralkyl, R_9 , $-(C=O)R_{15}$ and $-(C=O)R_9$;

or R_5 and R_6 taken together with the nitrogen to which they are attached form a substituted or unsubstituted heterocyclic radical, said heterocyclic radical optionally containing one to two additional heteroatoms independently selected from the group consisting nitrogen, oxygen, and sulfur;

or R_7 and R_8 taken together with the nitrogen to which they are attached form a substituted or unsubstituted heterocyclic radical, said heterocyclic radical optionally containing one to two additional heteroatoms independently selected from the group consisting nitrogen, oxygen, and sulfur;

said phenyl and heterocyclic radical substituents being at least one selected from the group consisting of alkyl, amino, hydroxy, carbonyl, monoalkylamino, dialkylamino, halogen, and alkoxy;

R_9 is a radical of the formula $-W-O(C=O)-CH_3$, W being a straight- or branched- chain alkylene group of 1 to 6 carbon atoms;

R₁₀ and R₁₁ are radicals independently selected from the group consisting of alkyl, halo, haloalkyl, and polyfluoroalkyl;

R₁₄ is a hydroxyalkyl, alkoxyalkyl or cycloalkyl group;

R₁₅ is an alkyl, hydroxyalkyl, alkoxyalkyl or cycloalkyl group, and pharmaceutically acceptable salts of said compound.

Claim 37 (previously presented): A compound according to claim 36, selected from the group consisting of:

2,2'-[[3-(2,2,2-Trifluoroethyl)phenyl]methylene]bis[4-[(5-methyl-1H-tetrazol-1-yl)imino]methyl]]phenol;

2,2'-[[3-(4-Morpholinyl)phenyl]methylene]bis[4-[(5-methyl-1H-tetrazol-1-yl)imino]methyl]]phenol;

2,2'-[[3-(1-Piperidiny)phenyl]methylene]bis[4-[(5-methyl-1H-tetrazol-1-yl)imino]methyl]]phenol;

2,2'-[[3-(4-Morpholinylsulfonyl)phenyl]methylene]bis[4-[(5-methyl-1H-tetrazol-1-yl)imino]methyl]]phenol;

2,2'-[[3-(Methoxyethoxy)phenyl]methylene]bis[4-[(5-methyl-1H-tetrazol-1-yl)imino]methyl]]phenol;

2,2'-[[[3-Bis(phenylmethyl)amino]phenyl]methylene]bis[4-[(5-methyl-1H-tetrazol-1-yl)imino]methyl]]phenol;

2,2'-[[3-[1-(4-Methylpiperazinyl)methyl]phenyl]methylene]bis[4-[(5-methyl-1H-tetrazol-1-yl)imino]methyl]]phenol;

2,2'-[[3-(Diethylaminomethyl)phenyl]methylene]bis[4-[(5-methyl-1H-tetrazol-1-yl)imino]methyl]]phenol;

2,2'-[[3-(Dimethylaminomethyl)phenyl]methylene]bis[4-[(5-methyl-1H-tetrazol-1-yl)imino]methyl]]phenol;

2,2'-[[3-[4-(Morpholinyl)methyl]phenyl]methylene]bis[4-[(5-methyl-1H-tetrazol-1-yl)imino]methyl]]phenol;

2,2'-[[3-[N-(4-Hydroxybutyl)-N-ethylamino]phenyl]methylene]bis[4-[(5-methyl-1H-tetrazol-1-yl)imino]methyl]]phenol;

2,2'-[[3-[2-(1,1-Dioxide-2,3,4,5-tetrahydro)isothiazolyl]phenyl]methylene]bis[4-[(5-methyl-1H-tetrazol-1-yl)imino]methyl]]phenol;

2,2'-[[3-[N-(3-Hydroxypropyl)-N-ethylamino]phenyl]methylene]bis[4-[(5-methyl-1H-tetrazol-1-yl)imino]methyl]]phenol;

2,2'-[[3-[N-(2-Hydroxyethyl)-N-ethylamino]phenyl]methylene]bis[4-[(5-methyl-1H-tetrazol-1-yl)imino]methyl]]phenol;

2,2'-[[3-[1-(4-Hydroxypiperidiny)]phenyl]methylene]bis[4-[(5-methyl-1H-tetrazol-1-yl)imino]methyl]]phenol;

2,2'-[[3-[N-(3-Hydroxypropyl)-N-methylamino]phenyl]methylene]bis[4-[(5-methyl-1H-tetrazol-1-yl)imino]methyl]]phenol;

2,2'-[[3-[N-(4-Acetoxybutyl)-N-ethylamino]phenyl]methylene]bis[4-[(5-methyl-1H-tetrazol-1-yl)imino]methyl]]phenol;

2,2'-[[3-[N-(2-Hydroxyethyl)-N-methylamino]phenyl]methylene]bis[4-[(5-methyl-1H-tetrazol-1-yl)imino]methyl]]phenol;

2,2'-[[3-[N-(4-Hydroxybutyl)-N-methylamino]phenyl]methylene]bis[4-[(5-methyl-1H-tetrazol-1-yl)imino]methyl]]phenol;


2,2'-[[3-[N-(2-Hydroxyethyl)-N-propylamino]phenyl]methylene]bis[4-[(5-methyl-1H-tetrazol-1-yl)imino]methyl]]phenol;

2,2'-[[3-[N-(4-Hydroxybutyl)-N-propylamino]phenyl]methylene]bis[4-[(5-methyl-1H-tetrazol-1-yl)imino]methyl]]phenol;


2,2'-[[3-[N-(6-Hydroxyhexyl)-N-ethylamino]phenyl]methylene]bis[4-[(5-methyl-1H-tetrazol-1-yl)imino]methyl]]phenol; and

2,2'-[[3-[N-(5-Hydroxypentyl)-N-ethylamino]phenyl]methylene]bis[4-[(5-methyl-1H-tetrazol-1-yl)imino]methyl]]phenol.

Claim 38 (previously presented): The compound according to claim 36 having the formula:



Claim 39 (previously presented): The compound according to claim 36 having the formula:



Claim 40 (previously presented): The compound according to claim 36 having the name 2,2'-[[3-[N-(4-Hydroxybutyl)-N-ethylamino]phenyl]methylene]bis[4-[[[(5-methyl-1H-tetrazol-1-yl)imino]methyl]]phenol.

Claim 41 (previously presented): The compound according to claim 36 having the name 2,2'-[[[3-[N-(2-Hydroxyethyl)-N-methylamino]phenyl]methylene]bis[4-[[[(5-methyl-1H-tetrazol-1-yl)imino]methyl]]phenol].

Claim 42 (previously presented): The compound according to claim 36 having the name 2,2'-[[3-[N-(2-Hydroxyethyl)-N-ethylamino]phenyl]methylene]bis[4-[[[(5-methyl-1H-tetrazol-1-yl)imino]methyl]]phenol.

Claim 43 (currently amended): A pharmaceutical composition for treating or preventing pneumovirus infection, said composition comprising a compound according to claim 36 in an amount effective to attenuate infectivity of said virus, and a pharmaceutically acceptable carrier medium.

Claim 44 (previously presented): A pharmaceutical composition according to claim 43, further comprising at least one supplemental active agent selected from the group consisting of

interferon, ribavirin and an immunomodulator, an immunoglobulin, an anti-inflammatory agent, an antibiotic, an anti-viral and an anti-infective.

Claim 45 (previously presented): A pharmaceutical composition according to claim 43, wherein said pharmaceutically acceptable carrier medium comprises ethanol.

Claim 46 (previously presented): A pharmaceutical composition according to claim 43, wherein said pharmaceutically acceptable carrier medium comprises propylene glycol.

Claim 47 (previously presented): A pharmaceutical composition according to claim 43, wherein said pharmaceutically acceptable carrier medium comprises water.

Claim 48 (previously presented): A pharmaceutical composition according to claim 45, wherein said pharmaceutically composition comprises at least 50% ethanol.

Claim 49 (previously presented): A pharmaceutical composition according to claim 45, wherein said pharmaceutically composition comprises at least 60% ethanol.

Claim 50 (previously presented): A pharmaceutical composition according to claim 45, wherein said pharmaceutically composition comprises at least 70% ethanol.

Claim 51 (previously presented): A pharmaceutical composition according to claim 45, wherein said pharmaceutically composition comprises at least 80% ethanol.

Claim 52 (previously presented): A pharmaceutical composition according to claim 45, wherein said pharmaceutically composition comprises at least 90% ethanol.

Claim 53 (previously presented): A pharmaceutical composition according to claim 52, wherein said pharmaceutically composition comprises less than 5% water.

Claim 54 (previously presented): A pharmaceutical composition according to claim 45, wherein said pharmaceutically acceptable carrier medium comprises ethanol, water, and propylene glycol.

HAYES SOLOWAY P.C.
3450 E. SUNRISE DRIVE,
SUITE 140
TUCSON, AZ 85718
TEL. 520.882.7623
FAX. 520.882.7643

175 CANAL STREET
MANCHESTER, NH 03101
TEL. 603.668.1400
FAX. 603.668.8567

Claim 55 (previously presented): A pharmaceutical composition according to claim 54, wherein said pharmaceutically composition comprises about 85% ethanol, about 10% propylene glycol, and about 5% water.

Claim 56 (previously presented): A method of treatment of pneumovirus infection in a patient in need of said treatment, said method comprising administering to said patient a therapeutically effective amount of a compound according to claim 36.

Claim 57 (previously presented): A method as claimed in claim 56, wherein said compound is administered through inhalation or intubation.

Claim 58 (previously presented): A method as claimed in claim 56, wherein said compound is administered by an electrohydrodynamic delivery device.

Claim 59 (previously presented): A method as claimed in claim 56, wherein said electrohydrodynamic delivery device is hand-held.

Claim 60 (previously presented): A method as claimed in claim 58, wherein said electrohydrodynamic delivery device is disposable.

Claim 61 (previously presented): A method as claimed in claim 58, wherein said electrohydrodynamic delivery device is for a single user.


Claim 62 (previously presented): A method as claimed in claim 58, wherein said electrohydrodynamic delivery device comprises a removable mouthpiece.

Claim 63 (previously presented): A method as claimed in claim 58, wherein said electrohydrodynamic delivery device comprises a mask.

Claim 64 (previously presented): A method of treating cells in culture that are susceptible to infection by, or infected or contaminated with a pneumovirus, said method comprising administering to said cultures an effective amount of a compound according to claim 36.


Claim 65 (previously presented): A method of treating biological materials that are susceptible to infection by, or infected or contaminated with a pneumovirus, said method comprising administering to said materials an effective amount of a compound according to claim 36.

Claim 66 (previously presented): A compound having the formula:




wherein:

R_1' represents a radical selected from the group consisting of



alkoxyalkoxy, polyfluoroalkyl, dialkylaminoalkyl, R_9 , $-OR_9$,



R_2 and R_3 are each independently selected from the group consisting of straight or branched chain alkyl and hydrogen;

R_4 is a radical selected from the group consisting of a substituted or unsubstituted phenyl radical, an unsubstituted or substituted heterocyclic radical, and $-NR_{12}R_{13}$;

R_5 and R_7 are independently selected from the group consisting of alkoxyalkyl, hydroxyalkyl, polyhydroxyalkyl, aralkyl, R_9 , $-(C=O)R_{14}$ and $-(C=O)R_9$;

R_6 , R_8 , R_{12} , and R_{13} are independently selected from the group consisting of hydrogen, alkyl, alkoxyalkyl, polyfluoroalkyl, hydroxyalkyl, polyhydroxyalkyl, aralkyl, R_9 , $-(C=O)R_{15}$ and $-(C=O)R_9$;

or R_5 and R_6 taken together with the nitrogen to which they are attached form a substituted or unsubstituted heterocyclic radical, said heterocyclic radical optionally containing one to two additional heteroatoms independently selected from the group consisting nitrogen, oxygen, and sulfur;

or R_7 and R_8 taken together with the nitrogen to which they are attached form a substituted or unsubstituted heterocyclic radical, said heterocyclic radical optionally containing one to two additional heteroatoms independently selected from the group consisting nitrogen, oxygen, and sulfur;

said phenyl and heterocyclic radical substituents being at least one selected from the group consisting of alkyl, amino, hydroxy, carbonyl, monoalkylamino, dialkylamino, halogen, and alkoxy;

R_9 is a radical of the formula $-W-O(C=O)-CH_3$, W being a straight- or branched- chain alkylene group of 1 to 6 carbon atoms;


R_{10} and R_{11} are radicals independently selected from the group consisting of alkyl, halo, haloalkyl, and polyfluoroalkyl;

R_{14} is a hydroxyalkyl, alkoxyalkyl or cycloalkyl group;

R_{15} is an alkyl, hydroxyalkyl, alkoxyalkyl or cycloalkyl group, and pharmaceutically acceptable salts of said compound.


Claim 67 (cancelled).

Claim 68 (previously presented): A compound having the formula:




III

wherein R_b is selected from the group consisting of $-\text{CH}_2\text{OCH}_3$, $-\text{CH}_2\text{OCH}_2\text{CH}_3$, -


$\text{CH}(\text{CH}_3)\text{OCH}_2\text{CH}_3$, $-\text{CH}_2-\text{OCH}_2\text{CH}_2-\text{OCH}_3$, , $-\text{CH}_2-\text{OCH}_2\text{CH}_2-\text{Si}(\text{CH}_3)_3$, $-\text{CH}_3$, -
 $\text{CH}_2\text{C}_6\text{H}_5$, $-(\text{CH}_2)_2\text{Si}(\text{CH}_3)_3$, $-\text{CON}(\text{R}_c\text{R}_d)_2$, $-\text{CSN}(\text{R}_c\text{R}_d)_2$, and $-\text{PO}(\text{NR}_c\text{R}_d)_2$;

R_c and R_d are independently selected from an alkyl group;

R_1'' represents a radical selected from the group consisting of



alkoxyalkoxy, polyfluoroalkyl, dialkylaminoalkyl, R_9 , $-\text{OR}_9$,



R_2 and R_3 are each independently selected from the group consisting of straight or branched chain alkyl and hydrogen;

R_4 is a radical selected from the group consisting of a substituted or unsubstituted phenyl radical, an unsubstituted or substituted heterocyclic radical, and $-\text{NR}_{12}\text{R}_{13}$;

R_5 and R_7 are independently selected from the group consisting of alkoxyalkyl, hydroxyalkyl, polyhydroxyalkyl, aralkyl, R_9 , $-(\text{C}=\text{O})\text{R}_{14}$ and $-(\text{C}=\text{O})\text{R}_9$;

R_6 , R_8 , R_{12} , and R_{13} are independently selected from the group consisting of hydrogen, alkyl, alkoxyalkyl, polyfluoroalkyl, hydroxyalkyl, polyhydroxyalkyl, aralkyl, R_9 , $-(\text{C}=\text{O})\text{R}_{15}$ and $-(\text{C}=\text{O})\text{R}_9$;

or R_5 and R_6 taken together with the nitrogen to which they are attached form a substituted or unsubstituted heterocyclic radical, said heterocyclic radical optionally containing

one to two additional heteroatoms independently selected from the group consisting nitrogen, oxygen, and sulfur;

or R₇ and R₈ taken together with the nitrogen to which they are attached form a substituted or unsubstituted heterocyclic radical, said heterocyclic radical optionally containing one to two additional heteroatoms independently selected from the group consisting nitrogen, oxygen, and sulfur;

said phenyl and heterocyclic radical substituents being at least one selected from the group consisting of alkyl, amino, hydroxy, carbonyl, monoalkylamino, dialkylamino, halogen, and alkoxy;

R₉ is a radical of the formula -W-O(C=O)-CH₃, W being a straight- or branched- chain alkylene group of 1 to 6 carbon atoms;

R₁₀ and R₁₁ are radicals independently selected from the group consisting of alkyl, halo, haloalkyl, and polyfluoroalkyl;

R₁₄ is a hydroxyalkyl, alkoxyalkyl or cycloalkyl group; and

R₁₅ is an alkyl, hydroxyalkyl, alkoxyalkyl or cycloalkyl group.